Ask AI
Back Back
AE Management With CDK4 6 Inhibitors
FAQs: An Oncology Nurse’s Perspectives on the Management of Adverse Events Associated With CDK4/6 Inhibitor Use for Patients With HR+/HER2- Breast Cancer

Released: October 16, 2025

Ashley Martinez
Ashley Martinez, DNP, APRN, FNP-BC, AOCNP, CPHQ, NEA-BC, NPD-BC
Activity Information

Activity

Progress
1
Course Completed
Continue
Key Takeaways
  • Dose interruption with or without a subsequent dose reduction is recommended for grade ≥3 CDK4/6 inhibitor–associated neutropenia.
  • Patients receiving a CDK4/6 inhibitor should be advised to immediately report any new or worsening respiratory symptoms.
  • Frequent repetition of instructions about dosing and adverse effect management strategies improves patient adherence to treatment plans.

In this commentary, I address key questions posed by the audience during an educational workshop series for oncology nurses titled, “CDK4/6 Inhibitors in Breast Cancer: An Oncology Nurse’s Toolkit to Enhance Tolerability and Preserve Benefit” and held at Oncology Nursing Society “Mega” Chapter meetings and planned education days across the United States.

Of great importance, oncology nurses have a crucial role in the early detection and implementation of appropriate management strategies for the adverse events associated with CDK4/6 inhibitors in the care of patients with hormone receptor–positive/HER2-negative breast cancer who are receiving treatment with these agents. It is important to follow the instructions in the prescribing information to guide dose reduction strategies when a patient experiences treatment-induced toxicities.

How do you manage ribociclib-associated grade 2 neutropenia?
Regarding ribociclib, the risk of neutropenia is one of the warnings on the label. A complete blood count (CBC) should be performed before ribociclib is initiated, and CBC should be monitored every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and then as clinically indicated. If grade 1/2 neutropenia (absolute neutrophil count [ANC] 1000/mm3 to less than the lower limit of normal) develops while the patient is receiving ribociclib, no dose adjustment is needed.

If the patient experiences grade 3 neutropenia (ANC 500/mm3 to <1000/mm3), dose interruption until recovery to grade ≤2 is recommended. Thereafter, ribociclib should be reinitiated at the same dose level. If grade 3 neutropenia recurs, dose interruption until recovery is recommended with treatment resumption at the next lower dose level. For grade 4 neutropenia, dose interruption until recovery to grade ≤2 followed by treatment resumption at the next lower dose level is recommended. Dose reductions occur in 200-mg/day increments. If a dose reduction below 200 mg/day becomes necessary, treatment should be discontinued.

Regularly rechecking the CBC as indicated is important because, for some patients, it may take some time to recover from neutropenia. I have seen patients who have had to take a 2- to 4-week treatment holiday because their neutropenia did not recover in a timely manner. If a patient has travel plans during treatment interruption, it may become complicated to monitor CBCs. However, initiating a treatment break after CDK4/6 inhibitor–associated neutropenia at that time may be doable.

For patients with neutropenia, what instructions do you provide them regarding the prevention of infection?
For patients experiencing neutropenia, I would advise and strongly encourage them to include good handwashing and hand-sanitizing practices to prevent infection as this goes a long way. Avoiding family members and/or friends who are sick is another way of preventing infection. The use of additional strategies such as mask wearing is a personal choice depending on where they are going—whether it is a public place or a friend’s house.

How do you educate your patients to distinguish between CDK4/6 inhibitor–related diarrhea and symptoms that require urgent care?
Treatment-induced diarrhea vs patient-specific bowel movement frequency can be difficult to differentiate. As an oncology nurse, it is necessary to know the patient’s daily stool frequency at baseline before treatment is initiated. For instance, a patient with inflammatory bowel disease may have bowel movements 2-3 times per day whereas one without this condition may have bowel movements every other day.

Patients need to be educated regarding the importance of keeping themselves hydrated and the signs and symptoms of dehydration. Ensuring adequate electrolyte intake is essential, and conducting regular electrolyte monitoring, ideally on a monthly basis or as clinically indicated, can help support monitoring and achieving this goal. In certain situations, patients may need urgent care and intravenous fluids to fully manage diarrhea if the use of antiemetics or antidiarrheal medications alone is insufficient.

How do you manage abemaciclib-associated grade 2 interstitial lung disease (ILD)/pneumonitis?
It is important for patients receiving any CDK 4/6 inhibitor to be monitored for pulmonary symptoms or radiologic changes suggestive of ILD or pneumonitis because severe, life-threatening, or fatal events may occur with CDK4/6 inhibitor use. Pulmonary symptoms indicative of ILD/pneumonitis may include cough, dyspnea, and/or hypoxia.

For grade 1/2 ILD/pneumonitis, in general, no dose modification is required. However, for persistent or recurrent grade 2 ILD/pneumonitis without resolution to baseline or grade 1 with the use of maximal supportive care within 7 days, treatment should be withheld until toxicity resolution to baseline or grade ≤1 and then resumed at the next lower dose. When grade 2 ILD/pneumonitis occurs with abemaciclib, I would consider corticosteroid use as supportive care.

Patients receiving any CDK4/6 inhibitor should be advised to immediately report any new or worsening respiratory symptoms. For new and/or worsening respiratory symptoms, treatment should be interrupted and patients evaluated for ILD/pneumonitis. For patients with recurrent symptomatic, severe, or grade 3/4 ILD/pneumonitis, the CDK4/6 inhibitor should be permanently discontinued. As a best practice, it is important to involve a pulmonologist or your pulmonary team when ILD/pneumonitis is suspected, especially if the patient is symptomatic.

What are the factors to consider before selecting a CDK4/6 inhibitor for patients with preexisting congestive heart failure or diabetes?
Among the 3 available CDK4/6 inhibitors—abemaciclib, palbociclib and ribociclib—ribociclib is known to cause QT prolongation. Therefore, I would not recommend ribociclib for a patient with an underlying risk of developing QT prolongation. As such, obtaining a thorough cardiac history is essential. 

Regarding diabetes, I have not seen any specific issue(s) with the use of any of the 3 approved CDK4/6 inhibitors for patients with diabetes, especially if the diabetes is well controlled. Nonetheless, for patients with diabetes who are receiving CDK4/6 inhibitors, I would ensure that either their primary healthcare team is involved in their care or refer them to an endocrinologist.

What are some of the barriers that exist with incorporating patients’ treatment goals with the ability to provide optimal care, and how can oncology nurses collaborate with the multidisciplinary team to optimize treatment plans for patients receiving CDK4/6 inhibitors?
Financial barriers can be quite significant in the care of our patients, particularly for those with limited healthcare coverage. The cost of treatment can be quite high, and for some patients, insurance coverage for these medications is limited. Although financial assistance programs from drug manufacturers or others exist, some require donors to supply the funds. The financial burden of treatment can be quite distressing for some patients, particularly when they are already coping with the stress of a cancer diagnosis.

most especially if the patient is already dealing with multiple comorbid conditions precluding the use of other less costly therapies.

The type of treatment-associated adverse effects experienced and the ability to manage them safely at home can be another barrier. Some patients have stronger familial and/or psychosocial support than others, and some are better able to understand and apply the given instructions, making them better able to thrive during treatment with a CDK4/6 inhibitor.

At my institution, we find it very helpful when we partner with our pharmacy team. Pharmacists bring a deep understanding about the medications currently being received by the patient. They are good at calling patients and explaining dosing and adverse effect management strategies over time. With my patients, I try to repeat instructions about dosing and adverse effect management strategies as many times as possible, in both written and verbal forms, as I have found that this approach helps to ensure that patients are fully on board with the requirements.

Shortly after the initiation of treatment, my approach is to schedule a follow-up in-person clinic visit or telephone call with my patients simply to check up on how they are tolerating treatment. With every opportunity I get, I reiterate the adverse effect management strategies, and I find this approach to be extremely useful.

Your Thoughts?
What questions do you have regarding optimizing the care of your patients with hormone receptor–positive/HER2-negative breast cancer who are receiving treatment with a CDK4/6 inhibitor? Answer the polling question and join the conversation in the discussion box below.

Continue

Poll

1.

In your practice, which CDK4/6 inhibitor–associated adverse event do you find the most challenging to manage?

Submit